A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.
A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.
Not yet recruiting · NCT05320874 · Registry updated 2022-04-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors. | Advanced Solid Tumor | Not yet recruiting | Phase 1 | 2022-04-11 | NCT05320874 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Xuanzhu Biopharmaceutical Co., Ltd. | 11 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Cancer Hospital | Beijing | China | 208 |